相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma
Mary Jane Lim-Fat et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2020)
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2020)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2020)
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
Karisa C. Schreck et al.
CANCERS (2019)
On high-risk, low-grade glioma: What distinguishes high from low?
Marjolein Geurts et al.
CANCER (2019)
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Darren R. Hargrave et al.
CLINICAL CANCER RESEARCH (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Rimas V. Lukas et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Thomas Kaley et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Diffuse Infiltrating Oligodendroglioma and Astrocytoma
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adult IDH wild-type lower-grade gliomas should be further stratified
Abudumijit Aibaidula et al.
NEURO-ONCOLOGY (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
Michael Karsy et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2017)
Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification
Midea Gierke et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Survival and low-grade glioma: the emergence of genetic information
Elizabeth B. Claus et al.
NEUROSURGICAL FOCUS (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Capturing the Molecular and Biological Diversity of High-Grade Astrocytoma in Genetically Engineered Mouse Models
Lionel M.L. Chow et al.
Oncotarget (2015)
The Nature and Management of Metastatic Melanoma After Progression on BRAF Inhibitors: Effects of Extended BRAF Inhibition
Matthew M. K. Chan et al.
CANCER (2014)
Clinical and prognostic features of adult patients with gangliogliomas
Shlomit Yust-Katz et al.
NEURO-ONCOLOGY (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Anoop P. Patel et al.
SCIENCE (2014)
IDH1 and IDH2 Mutations in Gliomas
Adam L. Cohen et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2013)
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
David A. Reardon et al.
CANCER (2012)
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
M. J. van den Bent et al.
LANCET ONCOLOGY (2011)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
M Brada et al.
ANNALS OF ONCOLOGY (2001)
Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas
H Fujisawa et al.
LABORATORY INVESTIGATION (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
分享论文
